GlobeStar Therapeutics is a clinical-stage pharmaceutical company with a single drug program targeting Multiple Sclerosis. GlobeStar holds an exclusive worldwide license to Project Amethyst, a patented formulation of previously approved drugs intended to treat neurodegeneration caused by MS. The company has not yet conducted clinical trials or generated revenue, and is currently in pre-clinical development — engaging advisors, designing trials, and initiating discussions with the FDA on a regulatory pathway. GlobeStar funds operations through debt and equity financing, and management acknowledges substantial going-concern risk given the lack of secured funding. The company's intended commercial model has two tracks: in North America and Europe, GlobeStar plans to seek FDA approval directly, with the goal of eventually selling or licensing the treatment; in India and emerging markets, GlobeStar has contracted a partner (SMIHC) to manage trials, regulatory filings, and commercialization, in exchange for a 5% royalty on sales and 50% of sublicense revenue. GlobeStar's near-term strategy is to use India as a proof-of-concept market, reasoning that approval from India's drug regulator may be accepted across SMIHC's broader territory, before pursuing North American and European approvals.